These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3535018)

  • 1. The role of colloidal bismuth subcitrate in gastric ulcer and gastritis.
    Tytgat GN; Rauws E; Langenberg W
    Scand J Gastroenterol Suppl; 1986; 122():22-9. PubMed ID: 3535018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of peptic ulcer and chronic gastritis with bismuth salts].
    Rösch W
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():34-40. PubMed ID: 3687149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bismuth: effects on gastritis and peptic ulcer.
    Rokkas T; Sladen GE
    Scand J Gastroenterol Suppl; 1988; 142():82-6. PubMed ID: 3047853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol).
    Morris A; Brown P; Ali MR; Lane M; Palmer R
    N Z Med J; 1988 Oct; 101(856 Pt 1):651-4. PubMed ID: 3054641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study.
    Kang JY; Tay HH; Wee A; Guan R; Math MV; Yap I
    Gut; 1990 Apr; 31(4):476-80. PubMed ID: 2186982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
    Wagstaff AJ; Benfield P; Monk JP
    Drugs; 1988 Aug; 36(2):132-57. PubMed ID: 3053124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate.
    Loffeld RJ; Potters HV; Stobberingh E; Flendrig JA; van Spreeuwel JP; Arends JW
    Gut; 1989 Sep; 30(9):1206-12. PubMed ID: 2680795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis.
    Marshall BJ; Armstrong JA; Francis GJ; Nokes NT; Wee SH
    Digestion; 1987; 37 Suppl 2():16-30. PubMed ID: 3622946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of colloidal bismuth subcitrate in the short-term treatment of duodenal ulcer.
    Barbara L; Corinaldesi R; Rea E; Paternicò A; Stanghellini V
    Scand J Gastroenterol Suppl; 1986; 122():30-4. PubMed ID: 3535019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled trial comparing colloidal bismuth subcitrate tablets, cimetidine and placebo in the treatment of gastric ulceration.
    Tytgat GN; van Bentem N; van Olffen G; Dekker W; Rutgeerts L; de Boer J
    Scand J Gastroenterol Suppl; 1982; 80():31-8. PubMed ID: 6761850
    [No Abstract]   [Full Text] [Related]  

  • 12. Double blind trial of colloidal bismuth subcitrate versus placebo in Helicobacter pylori positive patients with non-ulcer dyspepsia.
    Vaira D; Holton J; Ainley C; Falzon M; Osborn J; D'Anna L; Romanos A; Chandrakumaran K; McNeil I
    Ital J Gastroenterol; 1992 Sep; 24(7):400-4. PubMed ID: 1392023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the modes of action of colloidal bismuth subcitrate.
    Hall DW
    Scand J Gastroenterol Suppl; 1989; 157():3-6; discussion 21-2. PubMed ID: 2665050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Campylobacter pyloridis and gastritis.
    Marshall BJ
    J Infect Dis; 1986 Apr; 153(4):650-7. PubMed ID: 3512736
    [No Abstract]   [Full Text] [Related]  

  • 15. Colloidal bismuth subcitrate in peptic ulcer disease.
    Tytgat GN
    S Afr Med J; 1986 Jul; 70(1):31-3. PubMed ID: 3523793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Campylobacter pylori-associated gastritis: attempts to eradicate the bacteria by various antibiotics and anti-ulcer regimens.
    Glupczynski Y; Burette A; Nyst JF; De Prez C; De Koster E; Deltenre M
    Acta Gastroenterol Belg; 1988; 51(4-5):329-37. PubMed ID: 2979039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [What is safe in the treatment of Campylobacter pylori-induced gastritis and Campylobacter pylori-associated peptic ulcer?].
    Menge H
    Internist (Berl); 1988 Nov; 29(11):745-54. PubMed ID: 3069787
    [No Abstract]   [Full Text] [Related]  

  • 18. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.
    Rauws EA; Langenberg W; Houthoff HJ; Zanen HC; Tytgat GN
    Gastroenterology; 1988 Jan; 94(1):33-40. PubMed ID: 3335295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.
    Marshall BJ; Goodwin CS; Warren JR; Murray R; Blincow ED; Blackbourn SJ; Phillips M; Waters TE; Sanderson CR
    Lancet; 1988 Dec 24-31; 2(8626-8627):1437-42. PubMed ID: 2904568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent experimental and clinical studies on the pharmacology of colloidal bismuth subcitrate.
    Elder JB
    Scand J Gastroenterol Suppl; 1986; 122():14-6. PubMed ID: 3535016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.